Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLORE: PDX in Relapsed Mantle Cell Lymphoma
NCT03219047Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2018
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial in mantle cell lymphoma (MCL) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Feasibility of PDX-directed therapies at 1 year. Started Dec 2018; status: completed.
02
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03219047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219047.